System and methods for performing saliva-based diagnostic screenings
US-2024420847-A1 · Dec 19, 2024 · US
TAZ/WWTR1 for diagnosis and treatment of cancer
US9316654B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9316654-B2 |
| Application number | US-201313919129-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 17, 2013 |
| Priority date | Oct 4, 2007 |
| Publication date | Apr 19, 2016 |
| Grant date | Apr 19, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
We provide an anti-TAZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of TAZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of TAZ in the cell.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating cancer, comprising: detecting upregulation of expression, amount or activity of TAZ/WWTR1 in a cancer cell obtained from a subject as compared to the expression, amount or activity of TAZ/WWTR1 in a control cell known to be non-cancerous, wherein said detecting comprises contacting said cell with an antibody or antigen-binding fragment thereof that specifically binds TAZ/WWTR1; and administering an anti-TAZ antibody agent to the subject that inhibits TAZ/WWTR1 expression or activity.
Assignees
Inventors
Classifications
Drug screening · CPC title
- G01N33/6893Primary
related to diseases not provided for elsewhere · CPC title
spanning the whole gene, or a large part of it · CPC title
Antineoplastic agents · CPC title
Tumour cells; Cancer cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9316654B2 cover?
- We provide an anti-TAZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of TAZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulat…
- Who is the assignee on this patent?
- Agency Science Tech & Res
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6893. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).